Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Longeveron Inc. - Class A Common stock (NQ: LGVN )

1.760 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
This Company Is On a Mission to Level the Playing Field for Retail Investors
Image provided by BlackBoxStocks The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Why Longeveron Shares Are Rising Today
Longeveron Inc (NASDAQ: LGVN) is trading higher Wednesday after the company announced initiation of the Phase 2a clinical trial of lomecel-B for the treatment of Alzheimer... 
Via Benzinga
Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases
Palm Beach, FL – January 5, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an... 
Via FinancialNewsMedia
Topics Death
Exposures Death
Exclusive: Longeveron Kickstarts Its Mid-Stage Alzheimer's Disease Trial
Longeveron Inc (NASDAQ: LGVN) has initiated its Phase 2a clinical trial evaluating Lomecel-B for Alzheimer’s disease (AD). The first patient has consented to... 
Via Benzinga
25 Stocks Moving In Tuesday's Mid-Day Session
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 64.6% to $18.99 as traders circulated a social media post on a potential short squeeze. Flotek Industries, Inc. (NYSE... 
Via Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
Gainers Pasithea Therapeutics Corp. (NASDAQ: KTTA) jumped 37.3% to $2.0182. Pasithea recently said it expanded its footprint with second Ketamine Therapy Clinic in the UK.... 
Via Benzinga
54 Biggest Movers From Thursday
Gainers 22nd Century Group, Inc. (NASDAQ: XXII) surged 38.6% to settle at $3.05. The FDA authorized marketing of tobacco products that help reduce exposure to and consumption of... 
Via Benzinga
5 Short Squeeze Candidates To Watch: Petros Pharmaceuticals, iSpecimen Top The List Again
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge movie. GameStop Corp (NY... 
Via Benzinga
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! 
Via InvestorPlace
Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options
Palm Beach, FL –December 21, 2021 – FinancialNewsMedia.com News Commentary – Systemic mastocytosis is rare disease which affects very few people and it causes due to C-kit mutation which leads to... 
Via FinancialNewsMedia
Exposures Product Safety
Longeveron Inc. (NASDAQ:LGVN) Long Term Investor Notice: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 12/17/2021 -- An investigation on behalf of current long-term investors in shares of Longeveron Inc. (NASDAQ:LGVN) concerning potential breaches of fiduciary duties by... 
Via SBWire
5 Short Squeeze Candidates To Watch: Petros Pharma Tops List With 254% Cost To Borrow, One Of Highest Figures On Record
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE: GME) and AMC Entertainment Holdings (NYSE: AMC... 
Via Benzinga
3 Predictions for the Stock Market in 2022
Precisely predicting what the market will do is an easy way to get everything wrong, but here are three trends to look for in 2022. 
Via InvestorPlace
Why Longeveron’s Good News Isn’t Telling Us the Whole Truth
LGVN stock has soared in 2021 with the latest upbeat FDA news but a closer look at Longeveron's financials tells a different story. 
Via InvestorPlace
Topics Initial Public Offering
Exposures Product Safety Securities Market
18 Stocks Moving in Friday's Pre-Market Session
Gainers Context Therapeutics Inc. (NASDAQ: CNTX) rose 48.6% to $9.30 in pre-market trading as the company announced data from ONA-XR in early breast cancer. The company said ONA-... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; US Initial Jobless Claims Drop To 52-Year Low
Following the market opening Thursday, the Dow traded down 0.22% to 35,676.45 while the NASDAQ fell 0.30% to 15,740.38. The S&P also fell, dropping 0.21% to 4,691.18. The U.S... 
Via Benzinga
Topics Stocks
Exposures US Equities
Systemic Lupus Erythematosus Treatment Market Projected To Reach $3.56 Billion By 2027
Palm Beach, FL –December 8, 2021 – FinancialNewsMedia.com News Commentary – Systemic Lupus Erythematosus is also known as lupus. It is an autoimmune disease that affects all parts of your body. The... 
Via FinancialNewsMedia
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. 
Via InvestorPlace
Exposures COVID-19
2 Big Stock Bets That Are Insiders Are Buying Now
Reddit users picked their favorite biotech stocks, and all of them have fallen this year. The insiders have a different buying strategy. 
Via InvestorPlace
Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)
HLHS is a rare congenital heart defect that affects approximately 1,000 babies in the U.S. per year Orphan Drug Designation confers certain benefits and may result in... 
Via Benzinga
Exposures Product Safety
Is Longeveron a Good Biotech Stock to Buy?
Stem cell therapies are back in vogue, at least for this Miami-based biotechnology company. 
Via The Motley Fool
58 Biggest Movers From Friday
Gainers Hagerty, Inc. (NYSE: HGTY) shares jumped 46.5% to close at $15.62. TuanChe Limited (NASDAQ: TC) gained 44.7% to settle at $3.30. IO Biotech, Inc. (NASDAQ: IOBT) shares... 
Via Benzinga
Mid-Afternoon Market Update: DocuSign Drops Following Weak Revenue Forecast; Longeveron Shares Climb
Toward the end of trading Friday, the Dow traded down 0.37% to 34,512.05 while the NASDAQ fell 2.28% to 15,029.99. The S&P also fell, dropping 1.13% to 4,525.40. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Day Market Update: Nasdaq Dips Over 400 Points; Marvell Technology Shares Rise Following Upbeat Earnings
Midway through trading Friday, the Dow traded down 0.77% to 34,373.98 while the NASDAQ fell 2.8% to 14,950.19. The S&P also fell, dropping 1.52% to 4,507.37. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
41 Stocks Moving In Friday's Mid-Day Session
Gainers IO Biotech, Inc. (NASDAQ: IOBT) jumped 42% to $11.74. The company, last month, priced its IPO at $14 per share. Celyad Oncology SA (NASDAQ: CYAD) shares jumped 38.7% to... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Mid-Morning Market Update: Markets Open Lower; Big Lots Issues Weak Profit Forecast
Following the market opening Friday, the Dow traded down 0.31% to 34,532.63 while the NASDAQ fell 1.44% to 15,160.41. The S&P also fell, dropping 0.60% to 4,549.65. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, investor! We're at the end of the week and it starts off with the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Longeveron Shares Gain After Lead Product Gets FDA Orphan Drug Tag For Type Of Congenital Heart Defect
The FDA has granted Orphan Drug designation to Longeveron Inc's (NASDAQ: LGVN) lead investigational product Lomecel-B for Hypoplastic left heart syndrome (... 
Via Benzinga
Exposures Product Safety
20 Stocks Moving in Friday's Pre-Market Session
Gainers BIOLASE, Inc. (NASDAQ: BIOL) rose 27.2% to $0.52 in pre-market trading. Biolase reporte in Form4 filing that President bought 70,000 shares at an average price of $0.45... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.